Related references
Note: Only part of the references are listed.Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature
Deepak M. W. Balak et al.
DERMATOLOGY AND THERAPY (2020)
Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe Psoriasis
Bela J. Shah et al.
INDIAN DERMATOLOGY ONLINE JOURNAL (2020)
Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study
Arvin Ighani et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2018)
Current developments in phototherapy for psoriasis
Akimichi Morita
JOURNAL OF DERMATOLOGY (2018)
Real-world use of apremilast for patients with psoriasis in Japan
Megumi Kishimoto et al.
JOURNAL OF DERMATOLOGY (2018)
Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial
Mamitaro Ohtsuki et al.
JOURNAL OF DERMATOLOGY (2017)
Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study
Mohn'd AbuHilal et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2016)
Current and Future Oral Systemic Therapies for Psoriasis
John B. Kelly et al.
DERMATOLOGIC CLINICS (2015)
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Immunology of Psoriasis
Michelle A. Lowes et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
P. H. Schafer et al.
CELLULAR SIGNALLING (2014)
Photo(chemo)therapy Reduces Circulating Th17 Cells and Restores Circulating Regulatory T Cells in Psoriasis
Takuya Furuhashi et al.
PLOS ONE (2013)
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
P. H. Schafer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases
Georg Schett et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2010)
Bath-PUVA therapy induces circulating regulatory T cells in patients with psoriasis
Chiyo Saito et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2009)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Share Paper
